GlassScriptPhysician profile
Matthew Brian Yoak
NPI 1922003219
$450.63
in general payments reported to CMS, 2019-2025
10 companies · $25.91 in 2025
The $25.91 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $67.66 · 2021: $25.94 · 2023: $33.67 · 2025: $25.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $110.40 | 2019 | |
| Misonix INC | $81.73 | 2020-2021 | |
| Mentor Worldwide LLC | $72.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.54 | 2019 | |
| Bioventus LLC | $33.67 | 2023 | |
| Smith+Nephew, INC. | $26.22 | 2019-2021 | |
| Abbvie INC. | $25.91 | 2025 | |
| Melinta Therapeutics, LLC | $20.00 | 2019 | |
| Amgen INC. | $15.94 | 2019 | |
| Genzyme Corporation | $15.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Yoak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.